Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
Gut and Liver · 15.07.2023 · 17 (4) · 610-619
DOI: 10.5009/gnl220400 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Gut and Liver, online erschienen am 17.02.2023. Verfasst von Tae Seop Lim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health and Welfare, Korea Health Industry Development Institute.
Abstract (Originalsprache)
Background/Aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is categorized into three subtypes: overweight/obese (OW), lean/normal weight with metabolic abnormalities, and diabetes mellitus (DM). We investigated whether fibrotic burden in liver differs across subtypes of MAFLD patients.
Methods
This cross-sectional multicenter study was done in cohorts of subjects who underwent a comprehensive medical health checkup between January 2014 and December 2020. A total of 42,651 patients with ultrasound-diagnosed fatty liver were included. Patients were classified as no MAFLD, OW-MAFLD, lean-MAFLD, and DM-MAFLD. Advanced liver fibrosis was defined based on the nonalcoholic fatty liver disease fibrosis score (NFS) or fibrosis-4 (FIB-4) index.
Results
The mean age of the patients was 50.0 years, and 74.1% were male. The proportion of patients with NFS-defined advanced liver fibrosis was the highest in DM-MAFLD (6.6%), followed by OW-MAFLD (2.0%), lean-MAFLD (1.3%), and no MAFLD (0.2%). The proportion of patients with FIB-4-defined advanced liver fibrosis was the highest in DM-MAFLD (8.6%), followed by lean-MAFLD (3.9%), OW-MAFLD (3.0%), and no MAFLD (2.0%). With the no MAFLD group as reference, the adjusted odds ratios (95% confidence intervals) for NFS-defined advanced liver fibrosis were 4.46 (2.09 to 9.51), 2.81 (1.12 to 6.39), and 9.52 (4.46 to 20.36) in OW-MAFLD, lean-MAFLD, and DM-MAFLD, respectively, and the adjusted odds ratios for FIB-4-defined advanced liver fibrosis were 1.03 (0.78 to 1.36), 1.14 (0.82 to 1.57), and 1.97 (1.48 to 2.62) in OW-MAFLD, lean-MAFLD, and DM-MAFLD.
Conclusions
Fibrotic burden in the liver differs across MAFLD subtypes. Optimized surveillance strategies and therapeutic options might be needed for different MAFLD subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Yongin Severance Hospital, Yongin, Korea.
- Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Ewha Womans University Medical Center, Seoul, Korea.
- Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
- Yonsei Liver Center, Severance Hospital, Seoul, Korea.
ORCID-Profile: Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong
Förderung
- Ministry of Health and Welfare
- Korea Health Industry Development Institute
Zitieren
APA
Lim, T. S., Chun, H. S., Kim, S. S., Kim, J. K., Lee, M., Cho, H. J., Kim, S. U., & Cheong, J. Y. (2023). Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes. Gut and Liver, 17(4), 610-619. https://doi.org/10.5009/gnl220400
Vancouver
Lim TS, Chun HS, Kim SS, Kim JK, Lee M, Cho HJ, et al. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes. Gut and Liver. 2023;17(4):610-619. doi:10.5009/gnl220400
BibTeX
@article{Lim2023,
author = {Lim, Tae Seop and Chun, Ho Soo and Kim, Soon Sun and Kim, Ja Kyung and Lee, Minjong and Cho, Hyo Jung and Kim, Seung Up and Cheong, Jae Youn},
title = {Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes},
journal = {Gut and Liver},
year = {2023},
volume = {17},
number = {4},
pages = {610--619},
doi = {10.5009/gnl220400}
}
EUVIMED